Search - tctmd.com

Displaying 21 - 40 of 53

Sort: Relevancy | Date

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

News Conference News ACC 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

April 04, 2022

No Mortality Difference Between PCI and CABG for Left Main CAD: Meta-analysis

News Conference News AHA 2021

No Mortality Difference Between PCI and CABG for Left Main CAD: Meta-analysis

Michael O'Riordan

November 15, 2021

Polygenic Risk Score IDs People at Risk for Early MI, Death

News Daily News

Polygenic Risk Score IDs People at Risk for Early MI, Death

October 26, 2021

Number of People With Hypertension Doubles Since 1990

News Daily News

Number of People With Hypertension Doubles Since 1990

August 26, 2021

Extended TAILOR-PCI Data Again Show No Gains for Genotype-Guided Meds

News Conference News ACC 2021

Extended TAILOR-PCI Data Again Show No Gains for Genotype-Guided Meds

Yael L. Maxwell

May 26, 2021

Complete 2-Year Data From Evolut Low-Risk Trial ‘Reassuring’ for TAVI

News Conference News EuroPCR 2021

Complete 2-Year Data From Evolut Low-Risk Trial ‘Reassuring’ for TAVI

Yael L. Maxwell

May 19, 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

March 16, 2021

Diabetes Influences Relative Effects of Ticagrelor, Prasugrel in ACS: ISAR-REACT 5

News Daily News

Diabetes Influences Relative Effects of Ticagrelor, Prasugrel in ACS: ISAR-REACT 5

October 09, 2020

PCI for Left Main CAD: Meta-analysis Finds No Increased Risk of Mortality

News Daily News

PCI for Left Main CAD: Meta-analysis Finds No Increased Risk of Mortality

Michael O'Riordan

June 12, 2020

New EXCEL Analysis Reignites Debate Over PCI for Left Main CAD

News Daily News

New EXCEL Analysis Reignites Debate Over PCI for Left Main CAD

Michael O'Riordan

June 01, 2020

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

September 10, 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

September 01, 2019

COAPT Quality-of-Life Analysis Points to Significant, Sustained Benefits in Health Status With MitraClip

News Conference News ACC 2019

COAPT Quality-of-Life Analysis Points to Significant, Sustained Benefits in Health Status With MitraClip

March 17, 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

News Conference News ACC 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Michael O'Riordan

March 17, 2019

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

March 01, 2019

Should We All Become Bayesians?

Presentation TCT 2018

Should We All Become Bayesians?

Presenter: Stuart J. Pocock, Jan G. P. Tijssen

September 23, 2018

DES Slightly Edge Out DCBs in Treatment of In-Stent Restenosis: Meta-analysis

News Conference News EuroPCR 2018

DES Slightly Edge Out DCBs in Treatment of In-Stent Restenosis: Meta-analysis

May 30, 2018

Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used

News Conference News TCT 2017

Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used

November 02, 2017

BIOFLOW V: ‘Ultrathin-Strut’ Stent Beats Out Xience at 12 Months

News Conference News ESC 2017

BIOFLOW V: ‘Ultrathin-Strut’ Stent Beats Out Xience at 12 Months

August 30, 2017

Memo for Meta-analyses: Put Quality Over Quantity, Says AHA

News Daily News

Memo for Meta-analyses: Put Quality Over Quantity, Says AHA

August 11, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.